2024
公益財団法人アステラス病態代謝研究会, アステラス病態代謝研究会 最優秀理事長賞

2024
公益財団法人アステラス病態代謝研究会, アステラス病態代謝研究会 優秀発表賞

2024
日本リウマチ学会, JCR Excellent Abstract Award

2023
アジア太平洋リウマチ学会, アジア太平洋リウマチ学会 優秀演題賞

2023
日本リウマチ学会, 日本リウマチ学会 APLARトラベルアワード

2023
欧州リウマチ学会, EULAR 2023 Abstract Award (Basic Science)

2023
日本リウマチ財団, 塩川美奈子・膠原病研究奨励賞

2023
日本リウマチ学会, JCR Excellent Abstract Award

2021
米国立衛生研究所, NIH Fellows Award for Research Excellence

2018
日本シェーグレン症候群学会, 第２７回 日本シェーグレン症候群学会 優秀演題賞

2018
日本骨免疫学会, 第４回 日本骨免疫学会 優秀演題賞

2018
日本リウマチ学会, 第６２回 日本リウマチ学会 優秀演題賞

2017
日本リウマチ学会, 第６１回 日本リウマチ学会 優秀演題賞

2017
医療・介護・教育研究財団, 第１１回 ふくおか臨床医学研究賞

2016
International Forum on Rheumatoid Arthritis, 第８回 関節リウマチ国際フォーラム 若手研究者賞

2016
日本炎症・再生医学会, 第３７回 日本炎症・再生医学会 奨励賞

2016
日本リウマチ学会, 第６０回 日本リウマチ学会 奨励賞

2016
日本リウマチ学会, 第６０回 日本リウマチ学会 優秀演題賞

2015
日本炎症・再生医学会, 第３６回 日本炎症・再生医学会 優秀演題賞

2015
産業医科大学, 第３３回 産業医科大学学会総会学会長賞

2015
日本リウマチ学会, 第５９回 日本リウマチ学会 優秀演題賞

2014
日本インターフェロン・サイトカイン学会, 第１１回 日本インターフェロン・サイトカイン学会 奨励賞

2013
日本炎症・再生医学会, 第３４回 日本炎症・再生医学会 優秀演題賞

2012
日本炎症・再生医学会, 第３３回 日本炎症・再生医学会 優秀演題賞

2011
日本リウマチ学会, 第５５回 日本リウマチ学会 優秀演題賞

Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study
Takafumi Aritomi; Koshiro Sonomoto; Shingo Nakayamada; Hiroaki Tanaka; Atsushi Nagayasu; Satoshi Kubo; Ippei Miyagawa; Ayako Yamaguchi; Naoaki Ohkubo; Yasuyuki Todoroki; Yurie Satoh‐Kanda; Masanobu Ueno; Ryuichiro Kanda; Yuya Fujita; Masashi Funada; Hidenori Sakai; Satsuki Matsunaga; Hiroaki Tanaka; Masayuki Shinojima; Hiroki Kawamura; Kazuki Takahashi; Miyabi Ando; Kazuki Haru; Yusuke Miyazaki; Kentaro Hanami; Masao Nawata; Shunsuke Fukuyo; Keisuke Nakatsuka; Mikiko Tokunaga; Kazuyoshi Saito; Yoshiya Tanaka
Arthritis & Rheumatology, Apr. 2026

Impact of trial exclusion criteria on real-world comparative effectiveness of targeted therapies in rheumatoid arthritis: the FIRST Registry
Satoshi Kubo; Yoshiya Tanaka; Yusuke Miyazaki; Hiroaki Tanaka; Hidenori Sakai; Ryuichiro Kanda; Yuya Fujita; Masanobu Ueno; Yasuyuki Todoroki; Ippei Miyagawa; Shingo Nakayamada
RMD Open, Apr. 2026

Rheumatoid arthritis at a turning point in the era of targeted therapies
Satoshi Kubo
Modern Rheumatology, Mar. 2026

Effectiveness and safety of sarilumab in polymyalgia rheumatica: A retrospective study of the FIRST registry
Naoaki Ohkubo; Yusuke Miyazaki; Satoshi Kubo; Ippei Miyagawa; Koshiro Sonomoto; Yoshino Inoue; Yurie Satoh-Kanda; Hiroaki Tanaka; Masanobu Ueno; Atsushi Nagayasu; Takafumi Aritomi; Ryuichiro Kanda; Yuya Fujita; Masashi Funada; Hidenori Sakai; Kiyotake Yoshioka; Mayu Nishimoto; Kazuki Takahashi; Shingo Nakayamada; Yoshiya Tanaka
Modern Rheumatology, Mar. 2026

Comment on: Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: reply
Satoshi Kubo; Yoshiya Tanaka
Rheumatology, Jan. 2026

Real-world effectiveness of b/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry
Hidenori Sakai; Koshiro Sonomoto; Shingo Nakayamada; Masanobu Ueno; Atsushi Nagayasu; Takafumi Aritomi; Hiroaki Tanaka; Satoshi Kubo; Ippei Miyagawa; Yasuyuki Todoroki; Yurie Satoh-Kanda; Yuya Fujita; Ryuichiro Kanda; Yoshiya Tanaka
RMD Open, Jan. 2026

Predicting the progression of difficult-to-treat rheumatoid arthritis by a machine learning scoring system, from the FIRST registry
Masanobu Ueno; Koshiro Sonomoto; Hiroaki Tanaka; Atsushi Nagayasu; Takafumi Aritomi; Ippei Miyagawa; Satoshi Kubo; Yusuke Miyazaki; Yasuyuki Todoroki; Yurie Satoh-Kanda; Yuya Fujita; Hidenori Sakai; Shingo Nakayamada; Yoshiya Tanaka
RMD Open, Jan. 2026

Impact of glucocorticoid tapering speed on renal outcomes in proliferative lupus nephritis: a multicentre retrospective study
Koichiro Ohmura; Hayato Shimizu; Yoshiya Tanaka; Keiju Hiromura; Hiroki Hayashi; Kazuro Kamada; Kentaro Minowa; Yutaka Kawahito; Akiho Iwashita; Shinya Kaname; Shinsuke Yasuda; Kazuoto Hiramoto; Shoichi Maruyama; Nobuyuki Yajima; Yasunori Iwata; Isao Matsumoto; Takahisa Gono; Hiroko Sato; Satoshi Kubo; Singo Nakayamada; Hidekazu Ikeuchi; Yukio Yuzawa; Michihito Kono; Naoto Tamura; Takahiro Seno; Takashi Kida; Aki Sakashita; Akira Onishi; Akio Morinobu; Takahisa Kawakami; Tadashi Hosoya; Taiki Yamaguchi; Yuko Kaneko; Hironari Hanaoka; Sawako Kato; Kayaho Maeda; Shiori Nakagawa; Yuya Kondo; Masataka Kuwana; Tomonori Ishii; Shuji Sumitomo; Chisato Miyakoshi; Tatsuya Atsumi
Rheumatology, Sep. 2025

Spontaneous Remission in a Patient with Anti-OJ Autoantibodies-positive Anti-synthetase Syndrome Following SARS-CoV-2 Infection and mRNA Vaccination
Yasuyuki Todoroki; Shingo Nakayamada; Ippei Miyagawa; Satoshi Kubo; Kiyotake Yoshioka; Minoru Satoh; Yoshiya Tanaka
Internal Medicine, Sep. 2025

機械学習を用いたスコアリングシステムによるDifficult to treat RA(D2T RA)進展予測 FIRST registry
上野 匡庸; 園本 格士朗; 田中 宏明; 永安 敦; 有冨 貴史; 宮川 一平; 久保 智史; 宮崎 佑介; 轟 泰幸; 神田 友梨恵; 藤田 悠哉; 酒井 秀典; 中山田 真吾; 田中 良哉
九州リウマチ, Sep. 2025

関節リウマチにおけるb/tsDMARDs導入前CTの潜在性結核感染症検出と結核発症予防への有効性 FIRST registry
船田 将史; 宮崎 佑介; 中山田 真吾; 久保 智史; 園本 格士朗; 宮川 一平; 神田 友梨恵; 田中 宏明; 轟 泰幸; 上野 匡庸; 永安 敦; 有冨 貴史; 藤田 悠哉; 酒井 秀典; 田中 良哉
九州リウマチ, Sep. 2025

関節リウマチに伴う間質性肺疾患における治療マネジメント FIRST registryより
神田 龍一郎; 宮崎 佑介; 中山田 真吾; 久保 智史; 園本 格士朗; 宮川 一平; 山口 絢子; 神田 友梨恵; 田中 宏明; 轟 泰幸; 上野 匡庸; 永安 敦; 藤田 悠哉; 有冨 貴史; 田中 良哉
九州リウマチ, Sep. 2025

関節リウマチにおける生物学的/分子標的合成抗リウマチ薬開始後長期の骨密度の変化 FIRSTレジストリより
有冨 貴史; 園本 格士朗; 中山田 真吾; 田中 宏明; 久保 智史; 宮川 一平; 山口 絢子; 大久保 直紀; 上野 匡庸; 田中 良哉
九州リウマチ, Sep. 2025

Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from the FIRST registry.
Satoshi Kubo; Yusuke Miyazaki; Hiroaki Tanaka; Yuya Fujita; Hidenori Sakai; Masanobu Ueno; Yasuyuki Todoroki; Yurie Satoh-Kanda; Ippei Miyagawa; Shingo Nakayamada; Yoshiya Tanaka
Rheumatology (Oxford, England), Sep. 2025

Association of exercise-induced pulmonary hypertension with nailfold capillary density in systemic sclerosis: a single-center retrospective observational study.
Katsuhide Kusaka; Satoshi Kubo; Shingo Nakayamada; Ippei Miyagawa; Yusuke Miyazaki; Yurie Kanda; Yasuyuki Todoroki; Masanobu Ueno; Ryuichiro Kanda; Koshi Setoyama; Masaharu Kataoka; Yoshiya Tanaka
Arthritis research & therapy, Aug. 2025

Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis.
Atsushi Nagayasu; Yusuke Miyazaki; Koshiro Sonomoto; Satoshi Kubo; Ippei Miyagawa; Ayako Yamaguchi; Hiroaki Tanaka; Yasuyuki Todoroki; Masanobu Ueno; Takafumi Aritomi; Yuya Fujita; Hidenori Sakai; Katsunori Suzuki; Shingo Nakayamada; Yoshiya Tanaka
Rheumatology and therapy, Aug. 2025

Distribution of nailfold videocapillaroscopy parameters in systemic lupus erythematosus and their association with disease activity: an international blinded case–control analysis on behalf of the EULAR study group on microcirculation in rheumatic diseases
Francesca Ingegnoli; Nicola Ughi; Valeria Riccieri; Katia Stefanantoni; Jean-Luc Cracowski; Marwin Gutierrez; Alberto Sulli; Tatiana S Rodriguez-Reyna; Alexandra Hame; Ashima Makol; Laura Nuño-Nuño; Juan Carlos Nieto-Gonzalez; Satoshi Kubo; Malgorzata Michalska-Jakubus; Olga Sanchez Pernaute; Rossella De Angelis; Ariane L Herrick; Karin Melsens; Maurizio Cutolo; Vanessa Smith
RMD Open, Jul. 2025

Predictors of the effectiveness of first-line CTLA4-Ig in patients with RA: the FIRST registry
Hiroki Kobayashi; Yusuke Miyazaki; Shingo Nakayamada; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ayako Yamaguchi; Yoshino Inoue; Yasuyuki Todoroki; Hiroko Miyata; Hiroaki Tanaka; Yoshihisa Fujino; Shintaro Hirata; Yoshiya Tanaka
Rheumatology, May 2025

The 2023 revised diagnostic criteria for IgG4-related dacryoadenitis and sialadenitis
Masatoshi Kanda; Ken Nagahata; Masafumi Moriyama; Ken-ichi Takano; Ryuta Kamekura; Hajime Yoshifuji; Hiroto Tsuboi; Motohisa Yamamoto; Hisanori Umehara; Masataka Umeda; Mizuki Sakamoto; Takashi Maehara; Yoshino Inoue; Satoshi Kubo; Tetsuo Himi; Tomoki Origuchi; Yasufumi Masaki; Tsuneyo Mimori; Hiroaki Dobashi; Yoshiya Tanaka; Seiji Nakamura; Hiroki Takahashi
Modern Rheumatology, Apr. 2025

The abundance of regulatory T cell subsets is associated with the clinical outcomes of sarcoidosis
Katsuhide Kusaka; Yusuke Miyazaki; Shingo Nakayamada; Satoshi Kubo; Ippei Miyagawa; Yurie Satoh-Kanda; Yasuyuki Todoroki; Masanobu Ueno; Yoshiya Tanaka
Modern Rheumatology, Apr. 2025

Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry.
Ryuichiro Kanda; Yusuke Miyazaki; Shingo Nakayamada; Shunsuke Fukuyo; Satoshi Kubo; Ippei Miyagawa; Ayako Yamaguchi; Yurie Satoh-Kanda; Naoaki Ohkubo; Yasuyuki Todoroki; Hiroaki Tanaka; Masanobu Ueno; Atsushi Nagayasu; Yuya Fujita; Takafumi Aritomi; Katsuhide Kusaka; Hidenori Sakai; Satsuki Matsunaga; Hirotsugu Nohara; Yoshiya Tanaka
Rheumatology and therapy, Apr. 2025

Pursuing Precision Medicine in Managing Rheumatoid Arthritis
Satoshi Kubo; Yoshiya Tanaka
International Journal of Rheumatic Diseases, Apr. 2025

Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry
Hidenori Sakai; Yusuke Miyazaki; Shingo Nakayamada; Satoshi Kubo; Kentaro Hanami; Shunsuke Fukuyo; Ayako Yamaguchi; Ippei Miyagawa; Masanobu Ueno; Hiroaki Tanaka; Yasuyuki Todoroki; Naoaki Ohkubo; Masashi Funada; Satsuki Matsunaga; Yoshiya Tanaka
Rheumatology, Apr. 2025

Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry
Yusuke Miyazaki; Shingo Nakayamada; Hiroaki Tanaka; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ippei Miyagawa; Ayako Yamaguchi; Yasuyuki Todoroki; Yoshino Inoue; Masanobu Ueno; Yoshiya Tanaka
Rheumatology, Apr. 2025

Accelerated Type VII collagen turnover in systemic sclerosis patients, reflected by serological neo-epitope fragment biomarkers
Yi He; Jannie M B Sand; Satoshi Kubo; Naoaki Ohkubo; Yusuke Miyazaki; Morten Karsdal; Yoshiya Tanaka; Anne-Christine Bay-Jensen
Arthritis Research & Therapy, Mar. 2025

非典型的な画像所見を呈した再発性多発軟骨炎の1例
治 和樹; 中山田 真吾; 宮川 一平; 有冨 貴史; 久保 智史; 神田 友梨恵; 轟 泰幸; 上野 匡庸; 吉松 克真; 定直 日菜; 田中 文啓; 田中 良哉
九州リウマチ, Mar. 2025

Association of peripheral CD8+ T cell activation with disease activity and treatment resistance in systemic lupus erythematosus
Yuya Fujita; Shingo Nakayamada; Satoshi Kubo; Yusuke Miyazaki; Koshiro Sonomoto; Hiroaki Tanaka; Yoshiya Tanaka
RMD Open, Feb. 2025

Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness
Satoshi Kubo; Yusuke Miyazaki; Takahiro Nishino; Yuya Fujita; Michihiro Kono; Tsugumi Kawashima; Kazuyoshi Ishigaki; Katsuhide Kusaka; Hiroaki Tanaka; Masanobu Ueno; Yurie Satoh-Kanda; Yoshino Inoue; Yasuyuki Todoroki; Ippei Miyagawa; Kentaro Hanami; Shingo Nakayamada; Yoshiya Tanaka
Annals of the Rheumatic Diseases, Feb. 2025

A case of Buerger’s disease with vasculopathy and skin fibrosis requiring differential diagnosis from systemic sclerosis
Masashi Funada; Shingo Nakayamada; Shunsuke Fukuyo; Satoshi Kubo; Aya Nawata; Yuya Fujita; Yoshiya Tanaka
Modern Rheumatology Case Reports, Jan. 2025

Regulation of fibronectin and collagens type I, III and VI by TNF-α, TGF-β, IL-13, and tofacitinib
Frederik S. Gillesberg; Martin Pehrsson; Anne-Christine Bay-Jensen; Peder Frederiksen; Morten Karsdal; Bent W. Deleuran; Tue W. Kragstrup; Satoshi Kubo; Yoshiya Tanaka; Joachim H. Mortensen
Scientific Reports, Jan. 2025

Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry
Yusuke Miyazaki; Shingo Nakayamada; Hiroaki Tanaka; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ayako Yamaguchi; Ippei Miyagawa; Yurie Satoh-Kanda; Yasuyuki Todoroki; Yoshino Inoue; Masanobu Ueno; Yoshiya Tanaka
RMD Open, Jan. 2025

Induction of interleukin 21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus
Masanobu Ueno; Shigeru Iwata; Kaoru Yamagata; Yasuyuki Todoroki; Koshiro Sonomoto; Atsushi Nagayasu; Ippei Miyagawa; Satoshi Kubo; Yusuke Miyazaki; Hiroko Miyata; Ryuichiro Kanda; Takafumi Aritomi; Shingo Nakayamada; Yoshiya Tanaka
RMD Open, Dec. 2024

The immune health metric as an indicator of health and disease
Satoshi Kubo; Yoshiya Tanaka
Nature Reviews Rheumatology, Dec. 2024

AMBRA1 controls the translation of immune-specific genes in T lymphocytes
Simone Gottlieb; Wanjing Shang; Deji Ye; Satoshi Kubo; Ping Du Jiang; Samantha Shafer; Leilei Xu; Lixin Zheng; Ann Y. Park; Jian Song; Waipan Chan; Zhiqin Zeng; Tingyan He; Benjamin Schwarz; Björn Häupl; Thomas Oellerich; Michael J. Lenardo; Yikun Yao
Proceedings of the National Academy of Sciences, Oct. 2024

全身性エリテマトーデス(SLE)におけるT-bet陽性CD11c+B細胞の臨床的特徴に関する検討
轟 泰幸; 久保 智史; 永安 敦; 上野 匡庸; 神田 龍一郎; 有冨 貴史; 酒井 秀典; 田中 宏明; 園本 格士朗; 井上 嘉乃; 宮崎 佑介; 宮川 一平; 中山田 真吾; 田中 良哉
九州リウマチ, Sep. 2024

Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry
Yusuke Miyazaki; Masashi Funada; Shingo Nakayamada; Koshiro Sonomoto; Hiroaki Tanaka; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ayako Yamaguchi; Ippei Miyagawa; Yasuyuki Todoroki; Masanobu Ueno; Yoshiya Tanaka
Rheumatology, Sep. 2024

Ageing Population and Landscape of Rheumatoid Arthritis Treatment in Japan
Satoshi Kubo; Yoshiya Tanaka
EMJ Rheumatology, Jul. 2024

CT informs detection and treatment options in rheumatoid arthritis complicated by pulmonary non-tuberculous mycobacterial disease from the FIRST registry
Masashi Funada; Yusuke Miyazaki; Shingo Nakayamada; Koshiro Sonomoto; Satoshi Kubo; Ippei Miyagawa; Hiroaki Tanaka; Yoshiya Tanaka
RMD Open, Jun. 2024

Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus
Yurie Satoh-Kanda; Shingo Nakayamada; Satoshi Kubo; Kaoru Yamagata; Aya Nawata; Hiroaki Tanaka; Shunpei Kosaka; Ryuichiro Kanda; Shan Yu; Yuya Fujita; Koshiro Sonomoto; Yoshiya Tanaka
RMD Open, Jun. 2024

Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in mixed connective tissue disease
Yasuyuki Todoroki; Minoru Satoh; Satoshi Kubo; Shunpei Kosaka; Shunsuke Fukuyo; Keisuke Nakatsuka; Kazuyoshi Saito; Shin Tanaka; Shingo Nakayamada; Yoshiya Tanaka
Rheumatology, Apr. 2024

Evolution of diagnostic criteria and new insights into clinical testing in mixed connective tissue disease; anti-survival motor neuron complex antibody as a novel marker of severity of the disease
Satoshi Kubo; Yoshiya Tanaka
Immunological Medicine, Apr. 2024

就労全身性エリテマトーデス(SLE)患者の治療と仕事の両立を目指した効果的かつ安全な治療法の構築 B細胞「細胞内代謝」を標的とした治療法の可能性
轟 泰幸; 久保 智史; 園本 格士朗; 上野 匡庸; 大久保 直紀; 永安 敦; 神田 龍一郎; 有冨 貴史; 山形 薫; 中山田 真吾; 田中 良哉
産業医科大学雑誌, Mar. 2024

Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies
Kim Lauper; Denis Mongin; Sytske Anne Bergstra; Denis Choquette; Catalin Codreanu; Jacques-Eric Gottenberg; Satoshi Kubo; Merete Lund Hetland; Florenzo Iannone; Eirik K. Kristianslund; Tore K. Kvien; Galina Lukina; Xavier Mariette; Dan C. Nordström; Karel Pavelka; Manuel Pombo-Suarez; Ziga Rotar; Maria J. Santos; Yoshiya Tanaka; Carl Turesson; Delphine S. Courvoisier; Axel Finckh; Cem Gabay
Joint Bone Spine, Mar. 2024

GIMAP5 deficiency reveals a mammalian ceramide-driven longevity assurance pathway
Ann Y. Park; Michael Leney-Greene; Matthew Lynberg; Justin Gabrielski; Xijin Xu; Benjamin Schwarz; Lixin Zheng; Arasu Balasubramaniyam; Hyoungjun Ham; Brittany Chao; Yu Zhang; Helen F. Matthews; Jing Cui; Yikun Yao; Satoshi Kubo; Jean Michel Chanchu; Aaron Morawski; Sarah A. Cook; Ping Jiang; Juan C. Ravell; Yan H. Cheng; Alex George; Aiman Faruqi; Alison M. Pagalilauan; Jenna R. E. Bergerson; Sundar Ganesan; Samuel D Chauvin; Jahnavi Aluri; Joy Edwards-Hicks; Eric Bohrnsen; Caroline Tippett; Habib Omar; Leilei Xu; Geoffrey W. Butcher; John Pascall; Elif Karakoc-Aydiner; Ayca Kiykim; Holden T. Maecker; İlhan Tezcan; Saliha Esenboga; Raul Jimenez Heredia; Deniz Akata; saban tekin; Altan Kara; Zarife Kuloglu; Emel Unal; Tanıl Kendirli; Figen Dogu; Esra Karabiber; T. Prescott Atkinson; Claude Cochet
Nature Immunology, Feb. 2024

Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping
Hiroaki Tanaka; Yukinori Okada; Shingo Nakayamada; Yusuke Miyazaki; Kyuto Sonehara; Shinichi Namba; Suguru Honda; Yuya Shirai; Kenichi Yamamoto; Satoshi Kubo; Katsunori Ikari; Masayoshi Harigai; Koshiro Sonomoto; Yoshiya Tanaka
Annals of the Rheumatic Diseases, Feb. 2024

Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry
Satoshi Kubo; Yusuke Miyazaki; Yasuyuki Todoroki; Atsushi Nagayasu; Ryuichiro Kanda; Takafumi Aritomi; Satsuki Matsunaga; Masanobu Ueno; Ippei Miyagawa; Koshiro Sonomoto; Kentaro Hanami; Shingo Nakayamada; Yoshiya Tanaka
Rheumatology and Therapy, Dec. 2023

JAK inhibitors for rheumatoid arthritis
Satoshi Kubo; Shingo Nakayamada; Yoshiya Tanaka
Expert Opinion on Investigational Drugs, Apr. 2023

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study
Satoshi Kubo; Yusuke Miyazaki; Koichi Amano; Kiyoshi Matsui; Hideto Kameda; Yoshino Inoue; Shingo Nakayamada; Takehisa Ogura; Yuko Kaneko; Kunihiro Yamaoka; Yoshiya Tanaka
RMD Open, Apr. 2023

Possible involvement of CXCR3-CXCR6 + CD4 + T cells in Langerhans cell histiocytosis
Akemi Tokutsu; Yosuke Okada; Akira Kurozumi; Kenichi Tanaka; Satoshi Kubo; Yoshiya Tanaka
Journal of Bone and Mineral Metabolism, Mar. 2023

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
Masanobu Ueno; Ippei Miyagawa; Takafumi Aritomi; Koichi Kimura; Shigeru Iwata; Kentaro Hanami; Syunsuke Fukuyo; Satoshi Kubo; Yusuke Miyazaki; Shingo Nakayamada; Yoshiya Tanaka
Arthritis Research & Therapy, Dec. 2022

Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD
Yasuyuki Todoroki; Satoshi Kubo; Kazuhisa Nakano; Yusuke Miyazaki; Masanobu Ueno; Yurie Satoh-Kanda; Ryuichiro Kanda; Ippei Miyagawa; Kentaro Hanami; Keisuke Nakatsuka; Kazuyoshi Saito; Shingo Nakayamada; Yoshiya Tanaka
Rheumatology, Nov. 2022

Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes
Masanobu Ueno; Ippei Miyagawa; Yusuke Miyazaki; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Shingo Nakayamada; Yoshiya Tanaka
Arthritis Research & Therapy, Oct. 2022

Comprehensive immunophenotypic analysis reveals the pathological involvement of Th17 cells in Graves' disease
Keiichi Torimoto; Yosuke Okada; Shingo Nakayamada; Satoshi Kubo; Akira Kurozumi; Manabu Narisawa; Yoshiya Tanaka
Scientific Reports, Oct. 2022

Early B cell factor 4 modulates FAS-mediated apoptosis and promotes cytotoxic function in human immune cells
Satoshi Kubo; Rhea Kataria; Yikun Yao; Justin Q. Gabrielski; Lixin Zheng; Tovah E. Markowitz; Waipan Chan; Jian Song; Arun K. Boddapati; Keita Saeki; Björn Häupl; Ann Y. Park; Yan H. Cheng; Jing Cui; Thomas Oellerich; Michael J. Lenardo
Proceedings of the National Academy of Sciences, Aug. 2022

Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes
Ippei Miyagawa; Shingo Nakayamada; Masanobu Ueno; Yusuke Miyazaki; Naoaki Ohkubo; Yoshino Inoue; Satoshi Kubo; Yoshiya Tanaka
Frontiers in Medicine, Jul. 2022

GIMAP6 regulates autophagy, immune competence, and inflammation in mice and humans
Yikun Yao; Ping Du Jiang; Brittany N. Chao; Deniz Cagdas; Satoshi Kubo; Arasu Balasubramaniyam; Yu Zhang; Bella Shadur; Adeeb NaserEddin; Les R. Folio; Benjamin Schwarz; Eric Bohrnsen; Lixin Zheng; Matthew Lynberg; Simone Gottlieb; Michael A. Leney-Greene; Ann Y. Park; Ilhan Tezcan; Ali Akdogan; Rahsan Gocmen; Sevgen Onder; Avi Rosenberg; Elizabeth J. Soilleux; Errin Johnson; Peter K. Jackson; Janos Demeter; Samuel D. Chauvin; Florian Paul; Matthias Selbach; Haydar Bulut; Menna R. Clatworthy; Zewen K. Tuong; Hanlin Zhang; Benjamin J. Stewart; Catharine M. Bosio; Polina Stepensky; Simon Clare; Sundar Ganesan; John C. Pascall; Oliver Daumke; Geoffrey W. Butcher; Andrew J. McMichael; Anna Katharina Simon; Michael J. Lenardo
Journal of Experimental Medicine, Jun. 2022

Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study.
Satoshi Kubo
Arthritis research & therapy, Apr. 2022

Mucus sialylation determines intestinal host-commensal homeostasis
Yikun Yao; Girak Kim; Samantha Shafer; Zuojia Chen; Satoshi Kubo; Yanlong Ji; Jialie Luo; Weiming Yang; Sebastian P. Perner; Chrysi Kanellopoulou; Ann Y. Park; Ping Jiang; Jian Li; Safa Baris; Elif Karakoc Aydiner; Deniz Ertem; Daniel J. Mulder; Neil Warner; Anne M. Griffiths; Chani Topf-Olivestone; Michal Kori; Lael Werner; Jodie Ouahed; Michael Field; Chengyu Liu; Benjamin Schwarz; Catharine M. Bosio; Sundar Ganesan; Jian Song; Henning Urlaub; Thomas Oellerich; Stacy A. Malaker; Lixin Zheng; Carolyn R. Bertozzi; Yu Zhang; Helen Matthews; Will Montgomery; Han-Yu Shih; Jiansheng Jiang; Marcus Jones; Aris Baras; Alan Shuldiner; Claudia Gonzaga-Jauregui; Scott B. Snapper; Aleixo M. Muise; Dror S. Shouval; Ahmet Ozen; Kuan-Ting Pan; Chuan Wu; Michael J. Lenardo
Cell, Mar. 2022

Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease
Satoshi Kubo; Ryuichiro Kanda; Aya Nawata; Yusuke Miyazaki; Akio Kawabe; Kentaro Hanami; Keisuke Nakatsuka; Kazuyoshi Saito; Shingo Nakayamada; Yoshiya Tanaka
RMD Open, Mar. 2022

Congenital iRHOM2 deficiency causes ADAM17 dysfunction and environmentally directed immunodysregulatory disease
Satoshi Kubo; Jill M. Fritz; Hayley M. Raquer-McKay; Rhea Kataria; Ivan Vujkovic-Cvijin; Ahmad Al-Shaibi; Yikun Yao; Lixin Zheng; Juan Zou; Alex D. Waldman; Xinyi Jing; Taylor K. Farley; Ann Y. Park; Andrew J. Oler; Adrian K. Charles; Melanie Makhlouf; Eman H. AbouMoussa; Reem Hasnah; Luis R. Saraiva; Sundar Ganesan; Abdulrahman Ahmed Al-Subaiey; Helen Matthews; Emilio Flano; Hyun Hee Lee; Alexandra F. Freeman; Asena Pınar Sefer; Ersin Sayar; Erkan Çakır; Elif Karakoc-Aydiner; Safa Baris; Yasmine Belkaid; Ahmet Ozen; Bernice Lo; Michael J. Lenardo
Nature Immunology, Jan. 2022

T helper cells expressing fractalkine receptor and bearing T follicular helper 1-like cell functions in patients with IgG4-related disease
Yoshino Inoue; Shingo Nakayamada; Satoshi Kubo; Kaoru Yamagata; Koshiro Sonomoto; Shigeru Iwata; Yusuke Miyazaki; Yoshiya Tanaka
Rheumatology, Dec. 2021

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
Masanobu Ueno; Ippei Miyagawa; Kazuhisa Nakano; Shigeru Iwata; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Yusuke Miyazaki; Akio Kawabe; Hiroko Yoshinari; Shingo Nakayamada; Yoshiya Tanaka
Arthritis Research & Therapy, Dec. 2021

Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study
Yusuke Miyazaki; Kazuhisa Nakano; Shingo Nakayamada; Satoshi Kubo; Shigeru Iwata; Kentaro Hanami; Shunsuke Fukuyo; Ippei Miyagawa; Ayako Yamaguchi; Akio Kawabe; Kazuyoshi Saito; Yoshiya Tanaka
Arthritis Research & Therapy, Dec. 2021

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting
Yusuke Miyazaki; Kazuhisa Nakano; Shingo Nakayamada; Satoshi Kubo; Yoshino Inoue; Yoshihisa Fujino; Yoshiya Tanaka
Annals of the Rheumatic Diseases, Sep. 2021

Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability.
Satoshi Kubo
Bone, Aug. 2020

The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries.
Satoshi Kubo
Rheumatology (Oxford, England), Aug. 2020

A wide perspective of targeted therapies for precision medicine in autoimmune diseases
Satoshi Kubo
Expert Review of Precision Medicine and Drug Development, Aug. 2020

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation.
Satoshi Kubo
Arthritis research & therapy, Jun. 2020

Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry.
Satoshi Kubo
Arthritis research & therapy, Jun. 2020

A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related disease.
Satoshi Kubo
Modern rheumatology case reports, May 2020

Interleukin-23 drives expansion of Thelper 17 cells through epigenetic regulation by signal transducer and activators of transcription 3 in lupus patients.
Satoshi Kubo
Rheumatology (Oxford, England), May 2020

Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators.
Satoshi Kubo
Modern rheumatology case reports, May 2020

The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus
Ippei Miyagawa; Kazuhisa Nakano; Shingo Nakayamada; Shigeru Iwata; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Akio Kawabe; Yusuke Miyazaki; Yoshino Inoue; Masanobu Ueno; Naoaki Ohkubo; Yuya Fujita; Yoshiya Tanaka
International Journal of Rheumatic Diseases, Apr. 2020

Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis
Satoshi Kubo
International Journal of Rheumatic Diseases, Apr. 2020

Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders
Satoshi Kubo
Modern Rheumatology, Mar. 2020

抗PD-1抗体投与により末梢血中濾胞性ヘルパーT細胞増加を伴う甲状腺機能低下に至った橋本病の1例
鳥本 桂一; 岡田 洋右; 久保 智史; 中山田 真吾; 田中 良哉
日本内分泌学会雑誌, Feb. 2020

バセドウ病の末梢血リンパ球フェノタイプ解析による薬剤抵抗性患者の選別に関する検討
黒住 旭; 岡田 洋右; 成澤 学; 鳥本 桂一; 宮崎 佑介; 久保 智史; 中山田 真吾; 田中 良哉
日本内科学会雑誌, Feb. 2020

5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study
Satoshi Kubo
Modern Rheumatology, Jan. 2020

Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease
Satoshi Kubo
Arthritis Research & Therapy, Dec. 2019

Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis
Satoshi Kubo
Rheumatology, Dec. 2019

In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors
Satoshi Kubo
Rheumatology, Nov. 2019

Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10
Satoshi Kubo
Bone, Nov. 2019

Fast track algorithm: How to differentiate a “scleroderma pattern” from a “non-scleroderma pattern”
Satoshi Kubo
Autoimmunity Reviews, Nov. 2019

Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update
Satoshi Kubo
Expert Review of Clinical Immunology, Jul. 2019

Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases✰
Satoshi Kubo
Seminars in Arthritis and Rheumatism, Jun. 2019

Scleroderma in an ice-cream shop worker
Satoshi Kubo
Rheumatology, Jun. 2019

An Autopsy Case with Cerebral Hemorrhaging due to disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis
Satoshi Kubo
Internal Medicine, Apr. 2019

Immunophenotype involved in IgG4-related disease
Satoshi Kubo
Modern Rheumatology, Mar. 2019

Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus
Satoshi Kubo
International Journal of Rheumatic Diseases, Mar. 2019

Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus
Satoshi Kubo
Clinical Immunology, Mar. 2019

Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis
Satoshi Kubo
Rheumatology, Feb. 2019

Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies
Satoshi Kubo
Rheumatology, Jan. 2019

Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis
Satoshi Kubo
Frontiers in Immunology, Dec. 2018

Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors
Satoshi Kubo
Annals of the Rheumatic Diseases, Sep. 2018

Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus
Satoshi Kubo
Frontiers in Immunology, Aug. 2018

IgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion
Satoshi Kubo
Internal Medicine, Aug. 2018

The role of nailfold videocapillaroscopy in patients with systemic sclerosis
Satoshi Kubo
Immunological Medicine, Jul. 2018

Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
Satoshi Kubo
Frontiers in Immunology, Jun. 2018

A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab
Satoshi Kubo
Lupus, Jun. 2018

Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching
Satoshi Kubo
Clinical Immunology, Jun. 2018

Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus
Satoshi Kubo
Lupus, Apr. 2018

Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease
Satoshi Kubo
Rheumatology, Mar. 2018

Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients.
Satoshi Kubo
Clinical and experimental rheumatology, Feb. 2018

B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus
Satoshi Kubo
Clinical Immunology, Jan. 2018

Pleurisy Caused by Mycobacterium abscessus in a Young Patient with Dermatomyositis: A Case Report and Brief Review of the Literature
Satoshi Kubo
Internal Medicine, 2018

Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis
Satoshi Kubo
Rheumatology, Jan. 2018

Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients
Satoshi Kubo
Arthritis & Rheumatology, Oct. 2017

Anti-PD-1 Antibody Therapy Induces Hashimoto's Disease with an Increase in Peripheral Blood Follicular Helper T Cells
Satoshi Kubo
Thyroid, Oct. 2017

Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study
Satoshi Kubo
Rheumatology, Aug. 2017

Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis.
Satoshi Kubo
Clinical and experimental rheumatology, Apr. 2017

Usefulness of nailfold videocapillaroscopy for systemic sclerosis
Satoshi Kubo
Inflammation and Regeneration, Dec. 2016

Chemical JAK inhibitors for the treatment of rheumatoid arthritis
Satoshi Kubo
Expert Opinion on Pharmacotherapy, Nov. 2016

Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice
Satoshi Kubo
Modern Rheumatology, Nov. 2016

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis
Satoshi Kubo
BioDrugs, Oct. 2016

Association of plasmacytoid dendritic cells with B cell infiltration in minor salivary glands in patients with Sjögren's syndrome
Satoshi Kubo
Modern Rheumatology, Sep. 2016

Baricitinib for the treatment of rheumatoid arthritis
Satoshi Kubo
Expert Review of Clinical Immunology, Sep. 2016

Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.
Satoshi Kubo
Clinical and experimental rheumatology, Aug. 2016

Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching
Satoshi Kubo
Annals of the Rheumatic Diseases, Jul. 2016

Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report
Satoshi Kubo
Endocrinology, Diabetes & Metabolism Case Reports, May 2016

JAK Inhibition Significantly Reduced Fibrogenesis in Rheumatoid Arthritis Patients
Shintaro Hirata; Natasja Staehr Gudman; Kentaro Hanami; Satoshi Kubo; Anne C. Bay-Jensen; Morten Asser Karsdal; Yoshiya Tanaka
ARTHRITIS & RHEUMATOLOGY, Oct. 2015, Not reviewed, No invitation

Amplification of IL-21 signalling pathway through Bruton’s tyrosine kinase in human B cell activation
Satoshi Kubo
Rheumatology, Aug. 2015

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
Satoshi Kubo
Annals of the Rheumatic Diseases, Feb. 2015

[Abnormal expression of chemokine receptor on B cells in patients with SLE].
Maiko Yoshikawa; Shingo Nakayamada; Shigeru Iwata; Satoshi Kubo; Naoki Yunoue; Sheau-Pey Wang; Yoshiya Tanaka
Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 2015

Activation of Syk in Peripheral Blood B Cells in Patients With Rheumatoid Arthritis: A Potential Target for Abatacept Therapy
Satoshi Kubo
Arthritis & Rheumatology, Jan. 2015

The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells
Satoshi Kubo
Annals of the Rheumatic Diseases, Dec. 2014

Characteristic Phenotype of Peripheral Blood Lymphocytes in Patients with IgG4-Related Disease, Comparing to Primary Sjogren Syndrome and Healthy Controls.
Shintaro Hirata; Shingo Nakayamada; Satoshi Kubo; Maiko Yoshikawa; Naoki Yunoue; Kazuhisa Nakano; Kunihiro Yamaoka; Kazuyoshi Saito; Yoshiya Tanaka
ARTHRITIS & RHEUMATOLOGY, Oct. 2014, Not reviewed, No invitation

Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia®as Biological Intensive Treatment for RA (ORBIT) study
Satoshi Kubo
Modern Rheumatology, Sep. 2014

Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events
Satoshi Kubo
Rheumatology, May 2014

Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study
Satoshi Kubo
Arthritis Research & Therapy, 2014

Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study
Satoshi Kubo
Modern Rheumatology, Jan. 2014

The possible mode of action of Tofacitinib, a JAK inhibitor
Satoshi Kubo
Inflammation and Regeneration, 2014

Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis
Satoshi Kubo
Modern Rheumatology, Nov. 2013

Repeated High Or Low Multi-Biomarker Disease Activity (VECTRA (R) DA Algorithm) Scores Associated With Radiographic Outcomes In Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors
Shintaro Hirata; Wanying Li; Nadine A. Defranoux; Rebecca Bolce; Eric H. Sasso; Satoshi Kubo; Shunsuke Fukuyo; Kentaro Hanami; Kunihiro Yamaoka; Kazuyoshi Saito; Yoshiya Tanaka
ARTHRITIS AND RHEUMATISM, Oct. 2013, Not reviewed, No invitation

Dopamine D2-like receptor signaling suppresses human osteoclastogenesis
Satoshi Kubo
Bone, Sep. 2013

P5-08  TofacitinibのRA患者末梢血リンパ球への影響 —治療効果，感染症発症の視点から—
園本 格士朗; 山岡 邦宏; 久保 智史; 前島 圭佑; 齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2013

P9-13  既存治療抵抗性の多発血管炎性肉芽腫症（ウェゲナー肉芽腫症：GPA）にリツキシマブ（RTX）が奏功した1例
石川 雄一; 齋藤 和義; 中山田 真吾; 山田 彩; 齋藤 昌大; 吉成 紘子; 宮崎 佑介; 久保 智史; 福與 俊介; 園本 格士朗; 中野 和久; 山岡 邦宏; 田中 良哉
日本臨床免疫学会会誌, 2013

W1-1  Tfh細胞とTh1細胞の分化における可塑性とSLEにおけるヘルパーT細胞バランス異常
湯之上 直樹; 中山田 真吾; 久保 智史; 好川 真以子; 齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2013

W7-4  SLEに対するB細胞制御療法とリンパ球動態からみた病態の多様性
中山田 真吾; 岩田 慈; 好川 真以子; 久保 智史; 湯之上 直樹; 山岡 邦宏; 齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2013

P1-06  Tfh細胞とTh1細胞の分化における可塑性とSLEにおけるヘルパーT細胞バランス異常
湯之上 直樹; 中山田 真吾; 久保 智史; 好川 真以子; 齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2013

Role of JAKs in myeloid cells and autoimmune diseases
Satoshi Kubo
Inflammation and Regeneration, 2013

Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study
Satoshi Kubo
Arthritis Research & Therapy, 2013

Correlation of A Multi-Biomarker Disease Activity (VECTRA (TM) DA) Score with Clinical Disease Activity and Its Components with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Tofacitinib.
Kunihiro Yamaoka; Satoshi Kubo; Koshiro Sonomoto; Shintaro Hirata; Guy Cavet; Rebecca Bolce; Michael W. Rowe; David Chernoff; Nadine Defranoux; Kazuyoshi Saito; Yoshiya Tanaka
ARTHRITIS AND RHEUMATISM, Oct. 2012, Not reviewed, No invitation

Discontinuation of Adalimumab without Functional and Radiographic Damage Progression After Achieving Sustained Remission in Patients with Rheumatoid Arthritis (the HONOR study): 1-Year Results.
Yoshiya Tanaka; Shintaro Hirata; Shunsuke Fukuyo; Masao Nawata; Satoshi Kubo; Kunihiro Yamaoka; Kazuyoshi Saito
ARTHRITIS AND RHEUMATISM, Oct. 2012, Not reviewed, No invitation

Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)
Satoshi Kubo
Modern Rheumatology, Jun. 2012

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells
Satoshi Kubo
Arthritis & Rheumatism, Jun. 2012

Discontinuation of Adalimumab Without Functional and Structural Progress After Attaining Remission in Patients with Rheumatoid Arthritis
Yoshiya Tanaka; Shintaro Hirata; Shunsuke Fukuyo; Masao Nawata; Satoshi Kubo; Kunihiro Yamaoka; Kazuyoshi Saito
ARTHRITIS AND RHEUMATISM, Oct. 2011, Not reviewed, No invitation

Tofacitinib Reduces Interferon-gamma and Interleukin-17 Production From CD4+T Cells in Patients with Rheumatoid Arthritis.
Satoshi Kubo; Kunihiro Yamaoka; Koshiro Sonomoto; Keisuke Maeshima; Shintaro Hirata; Kazuhisa Nakano; Norifumi Sawamukai; Masao Nawata; Shigeru Iwata; Kazuyoshi Saito; Yoshiya Tanaka
ARTHRITIS AND RHEUMATISM, Oct. 2011, Not reviewed, No invitation

Successful treatment of primary biliary cirrhosis with etanercept in a patient with rheumatoid arthritis
Satoshi Kubo
Joint Bone Spine, Oct. 2011

Phenotypic Changes of Lymphocytes in Patients with Systemic Lupus Erythematosus Who Are in Longterm Remission After B Cell Depletion Therapy with Rituximab
Satoshi Kubo
The Journal of Rheumatology, Apr. 2011

JAK inhibitor: tofacitinib, a new disease modifying anti-rheumatic drug
Satoshi Kubo
Inflammation and Regeneration, 2011

Pericarditis induced by prophylactic administration of isoniazid in a patient with rheumatoid arthritis
Satoshi Kubo
Joint Bone Spine, Jan. 2011

皮膚筋炎の若年患者におけるMycobacterium abscessusによって生じた胸膜炎　1症例報告と文献レビュー概要(Pleurisy Caused by Mycobacterium abscessus in a Young Patient with Dermatomyositis: A Case Report and Brief Review of the Literature)
Noguchi Shingo, Hanami Kentaro, Miyata Hiroko, Torii Ryo, Shimabukuro Ikuko, Kubo Satoshi, Obata Hideto, Yoshii Chiharu, Yatera Kazuhiro
Internal Medicine, Apr. 2018, Reviewed, Null

【関節リウマチ「真の寛解」と「安全性」を目指す治療】実地医家が知っておくべき関節リウマチの最新治療　T細胞選択的共刺激調整薬(CTLA4-Ig)
久保 智史, 田中 良哉
Medical Practice, Jul. 2019, Reviewed, No invitation
Lead

【膠原病・自己免疫疾患を「見える化」する】臨床から見える化する　強皮症　強皮症における微小血管障害を見える化する
久保 智史, 田中 良哉
Medicina, Nov. 2020, Reviewed, No invitation
Lead

【内科疾患における生物学的製剤の使い分け】 《生物学的製剤を極める》　ベリムマブ
久保 智史, 田中 良哉
Modern Physician, Sep. 2018, Reviewed, Null
Lead

【リウマチ・膠原病-病態に基づいた治療戦略】末梢血リンパ球サブセットによる病態解析と臨床応用
中山田 真吾, 宮川 一平, 久保 智史, 田中 良哉
カレントテラピー, May 2020, Reviewed, No invitation

混合性結合組織病における新規バイオマーカー　抗SMN complex抗体
轟 泰幸, 久保 智史, 田中 良哉
リウマチ科, Mar. 2025, Reviewed, No invitation

【病態を考慮した治療選択-ガイドラインからプレシジョンメディシンへ-】免疫学的背景を考慮したSLEの治療選択
久保 智史, 田中 良哉
リウマチ科, Dec. 2024, Reviewed, No invitation
Lead

【リウマチ性疾患診療における自己抗体アップデート】混合性結合組織病に関連した自己抗体
久保 智史, 田中 良哉
リウマチ科, Apr. 2024, Reviewed, No invitation
Lead

JAK阻害薬休薬の可能性　XANADU study
久保 智史, 田中 良哉
リウマチ科, Jan. 2024, Reviewed, No invitation
Lead

【JAK阻害薬の基礎と臨床】JAK阻害薬による自然免疫および適応免疫に対する作用
久保 智史, 田中 良哉
リウマチ科, Jul. 2019, Reviewed, No invitation
Lead

生物学的抗リウマチ薬の末梢血免疫細胞プロファイルに対する影響
中山田 真吾, 久保 智史, 田中 良哉
リウマチ科, Mar. 2019, Reviewed, No invitation

IL-21はSLEにおける自己反応性CD11c高発現T-bet陽性B細胞の増殖と形質細胞分化を促進する
久保 智史, 中山田 真吾, 田中 良哉
リウマチ科, Feb. 2019, Reviewed, No invitation
Lead

RA疾患活動性制御後のトファシチニブ休薬について
久保 智史, 田中 良哉
リウマチ科, Sep. 2018, Reviewed, Null
Lead

強皮症
久保智史，田中良哉
リウマチ科, Apr. 2018, Reviewed, No invitation
Lead

無症候性IgG4関連胆嚢炎を伴ったIgG4関連疾患の一例
日下 勝秀, 中野 和久, 吉成 紘子, 岩田 慈, 福與 俊介, 花見 健太郎, 久保 智史, 宮川 一平, 河邊 明男, 宮崎 佑介, 名和田 彩, 井上 嘉乃, 上野 匡庸, 有冨 貴史, 中山田 真吾, 田中 良哉
九州リウマチ, Mar. 2019, Reviewed, No invitation

外転神経麻痺で発症した好酸球性多発血管炎性肉芽腫症の一例
永安 敦, 中野 和久, 宮川 一平, 中山田 真吾, 岩田 慈, 福與 俊介, 久保 智史, 田中 良哉
九州リウマチ, Sep. 2018, Reviewed, Null

上大静脈症候群を呈した血管型ベーチェット病の1例
上野 匡庸, 中野 和久, 宮川 一平, 中山田 真吾, 岩田 慈, 福與 俊介, 久保 智史, 宮崎 佑介, 河邊 明男, 田中 良哉
九州リウマチ, Sep. 2018, Reviewed, Null

リツキシマブが奏効したオーバーラップ症候群(全身性エリテマトーデス・関節リウマチ・全身性強皮症)の一例
轟 泰幸, 久保 智史, 中野 和久, 中山田 真吾, 岩田 慈, 福與 俊介, 宮川 一平, 名和田 彩, 田中 良哉
九州リウマチ, Sep. 2018, Reviewed, Null

MPO-ANCA陽性を呈した抗GBM抗体型腎炎の1例
上野 匡庸, 中野 和久, 吉成 紘子, 中山田 真吾, 久保 智史, 宮川 一平, 好川 真以子, 田村 雅仁, 宮本 哲, 齋藤 和義, 田中 良哉
九州リウマチ, Apr. 2018, Reviewed, Null

アバタセプトの作用機序の新知見
中山田 真吾, 久保 智史, 田中 良哉
九州リウマチ, Mar. 2016, Null, Null

関節リウマチ(RA)のIFX療法における併用MTX増量の有効性の検証
名和田 雅夫, 齋藤 和義, 福與 俊介, 花見 健太郎, 久保 智史, 水野 泰志, 平田 信太郎, 山岡 邦宏, 田中 良哉
九州リウマチ, Mar. 2013, Null, Null

関節リウマチ(RA)に対するトシリズマブ(TCZ)療法におけるMTX併用量の有効性の検討
花見 健太郎, 田坂 文一, 平田 信太郎, 福與 俊介, 久保 智史, 水野 泰志, 齋藤 和義, 田中 良哉
九州リウマチ, Mar. 2013, Null, Null

【全身性強皮症-皮膚だけではなく全身性の自己免疫疾患】[Chapter 4]新規治療戦略　免疫フェノタイプによる層別化　精密医療への挑戦
久保 智史, 田中 良哉
内科, Jan. 2025, Reviewed, No invitation
Lead

【膠原病のすべて】膠原病の病態解明　免疫サブセット解析の最前線
久保 智史, 田中 良哉
医学のあゆみ, Feb. 2024, Reviewed, No invitation
Lead

【自己免疫疾患　層別化する新時代へ　臨床検体のマルチオミクス解析、腸内細菌によって見えてきた免疫経路の全容】(第1章)精密医療を目指したマルチオミクス解析によるアプローチ　イムノフェノタイピングによる自己免疫疾患の層別化医療
田中 良哉, 宮川 一平, 久保 智史, 中山田 真吾
実験医学, Sep. 2022, Reviewed, No invitation

関節リウマチの予後予測因子 Multi-biomarker disease activity(MBDA)スコアは関節リウマチにおけるTNF阻害薬による構造的寛解を最も鋭敏に予測、反映する疾患活動性マーカーである
平田 信太郎, 齋藤 和義, 久保 智史, 福與 俊介, 水野 泰志, Li Wanying, Haney Douglas J., Defranoux Nadine, Bolce Rebecca, Cavet Guy, 園本 格士朗, 花見 健太郎, 岩田 慈, 名和田 雅夫, 澤向 範文, 中野 和久, 中山田 真吾, 山岡 邦宏, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの治療　新しい治療薬 JAK阻害薬tofacitinibはIRF7の発現抑制を介してtolerogenic DCを誘導する
久保 智史, 山岡 邦宏, 岩田 慈, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの治療　新しい治療薬 トファシチニブは生体内でT細胞に作用しIL-17産生を抑制して骨破壊抑制をもたらす
久保 智史, 山岡 邦宏, 園本 格士朗, 平田 信太郎, 福與 俊介, 中山田 真吾, 中野 和久, 澤向 範文, 名和田 雅夫, 岩田 慈, 水野 泰志, 齋藤 和義, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの病因・病態 濾胞性ヘルパーT細胞の可塑性と関節リウマチ病態形成における役割
中山田 真吾, 福與 俊介, 久保 智史, 岩田 慈, 湯之上 直樹, 山岡 邦宏, 中野 和久, 齋藤 和義, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

TNF阻害療法を導入した関節リウマチ患者におけるmulti-biomarkerによる客観的疾患活動性評価の検討
平田 信太郎, 齋藤 和義, 久保 智史, 福與 俊介, 水野 泰志, 岩田 慈, 名和田 雅夫, 山岡 邦宏, 田中 良哉
日本内科学会雑誌, Feb. 2013, Null, Null

【膠原病診療の進歩2024-世界最新のガイドライン,リコメンデーション-】プレシジョンメディシン
久保 智史, 田中 良哉
日本臨床, Aug. 2024, Reviewed, No invitation
Lead

【混合性結合組織病(MCTD)-診断と治療の最近の考え方-】臨床　MCTDに有用な臨床検査,生理機能検査
久保智史, 田中良哉
日本臨床, Mar. 2023, Reviewed, No invitation
Lead

JAK阻害薬tofacitinibの樹状細胞を介した免疫応答調節機構
久保 智史, 山岡 邦宏, 岩田 慈, 田中 良哉
日本臨床免疫学会会誌, Aug. 2012, Null, Null

臨床免疫領域におけるバイオマーカーの臨床的意義　混合性結合組織病(MCTD)における抗survival of motor neuron(SMN)complex抗体の臨床的意義
轟 泰幸, 佐藤 実, 久保 智史, 田中 晋, 中山田 真吾, 田中 良哉
日本臨床免疫学会総会プログラム・抄録集, Oct. 2022, Reviewed, Null

IgG4関連疾患における獲得免疫の役割
久保智史、田中良哉
日本臨牀, Mar. 2024, Reviewed, No invitation
Lead

リウマチ性疾患の臓器障害　リウマチ性疾患における多臓器障害のメカニズム
久保 智史, 田中 良哉
炎症と免疫, Jun. 2024, Reviewed, No invitation
Lead

【IgG4関連疾患の新展開】IgG4関連疾患における免疫細胞とサイトカイン
田中 良哉, 久保 智史, 井上 嘉乃, 中山田 真吾
炎症と免疫, Jun. 2020, Reviewed, No invitation

医学用語解説　プロペンシティスコア(Propensity score)
久保 智史, 田中 良哉
炎症と免疫, Jun. 2016, Null, Null

難治性線維化病態に対するイマチニブ少量療法の効果
澤向 範文, 久保 智史, 齋藤 和義, 山岡 邦宏, 田中 良哉
産業医科大学雑誌, Mar. 2013, Null, Null

単球系細胞のチロシンキナーゼJAKを介した職業性アレルギー病態調整機構
山岡 邦宏, 久保 智史, 尾下 浩一, 田中 良哉
産業医科大学雑誌, Mar. 2013, Null, Null

【SLEとAAVの新展開】現在治験中のSLEの新規薬剤(rozibafusp alfa, cenerimod)
久保 智史, 田中 良哉
腎と透析, Jun. 2023, Reviewed, No invitation
Lead

関節リウマチ治療における寛解の先
久保 智史, 田中 良哉
臨床リウマチ, Jun. 2024, Reviewed, No invitation
Lead

【自己免疫疾患】 強皮症
久保 智史, 田中 良哉
臨床免疫・アレルギー科, Apr. 2018, Reviewed, Null
Lead

【ここが変わった! 関節リウマチの治療】リウマチ患者さんの「困った!」「大丈夫?」に対処する　薬は減らせないの?　疾患活動性と希望に応じて減薬を処方医に相談する
久保智史, 田中良哉
薬局, Mar. 2023, Reviewed, No invitation
Lead

Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping.
Tanaka H, Okada Y, Nakayamada S, Miyazaki Y, Sonehara K, Namba S, Honda S, Shirai Y, Yamamoto K, Kubo S, Ikari K, Harigai M, Sonomoto K, Tanaka Y.
Annals of the Rheumatic Diseases, Oct. 2023, Reviewed, No invitation

Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness.
Kubo Satoshi, Miyazaki Yusuke, Nishino Takahiro, Fujita Yuya, Kono Michihiro, Kawashima Tsugumi, Ishigaki Kazuyoshi, Kusaka Katsuhide, Tanaka Hiroaki, Ueno Masanobu, Satoh-Kanda Yurie, Inoue Yoshino, Todoroki Yasuyuki, Miyagawa Ippei, Hanami Kentaro, Nakayamada Shingo, Tanaka Yoshiya
Annals of the rheumatic diseases, Oct. 2024, Reviewed, No invitation
Lead

Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness.
Kubo Satoshi, Miyazaki Yusuke, Nishino Takahiro, Fujita Yuya, Kono Michihiro, Kawashima Tsugumi, Ishigaki Kazuyoshi, Kusaka Katsuhide, Tanaka Hiroaki, Ueno Masanobu, Satoh-Kanda Yurie, Inoue Yoshino, Todoroki Yasuyuki, Miyagawa Ippei, Hanami Kentaro, Nakayamada Shingo, Tanaka Yoshiya
Annals of the rheumatic diseases, Feb. 2025, Reviewed, No invitation
Lead

Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping.
Tanaka Hiroaki, Okada Yukinori, Nakayamada Shingo, Miyazaki Yusuke, Sonehara Kyuto, Namba Shinichi, Honda Suguru, Shirai Yuya, Yamamoto Kenichi, Kubo Satoshi, Ikari Katsunori, Harigai Masayoshi, Sonomoto Koshiro, Tanaka Yoshiya
Annals of the rheumatic diseases, Jan. 2024, Reviewed, No invitation

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
Miyazaki Yusuke, Nakano Kazuhisa, Nakayamada Shingo, Kubo Satoshi, Inoue Yoshino, Fujino Yoshihisa, Tanaka Yoshiya
Annals of the rheumatic diseases, Sep. 2021, Reviewed, No invitation

Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors.
Ma Xiaoxue, Nakayamada Shingo, Kubo Satoshi, Sakata Kei, Yamagata Kaoru, Miyazaki Yusuke, Yoshikawa Maiko, Kitanaga Yukihiro, Zhang Mingzeng, Tanaka Yoshiya
Annals of the rheumatic diseases, Sep. 2018, Reviewed, No invitation

Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
Kubo Satoshi, Nakayamada Shingo, Nakano Kazuhisa, Hirata Shintaro, Fukuyo Shunsuke, Miyagawa Ippei, Hanami Kentaro, Saito Kazuyoshi, Tanaka Yoshiya
Annals of the rheumatic diseases, Jul. 2016, Reviewed, Null
Lead

The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Kubo Satoshi, Yamaoka Kunihiro, Kondo Masahiro, Yamagata Kaoru, Zhao Jidong, Iwata Shigeru, Tanaka Yoshiya
Annals of the rheumatic diseases, Dec. 2014, Null, Null

Peripheral immunophenotyping identifies three subgroups based on T cell heterogeneity in lupus patients.
Kubo Satoshi, Nakayamada Shingo, Yoshikawa Maiko, Miyazaki Yusuke, Sakata Kei, Nakano Kazuhisa, Hanami Kentaro, Iwata Shigeru, Miyagawa Ippei, Saito Kazuyoshi, Tanaka Yoshiya
Arthritis & rheumatology (Hoboken, N.J.), Jun. 2017, Reviewed, No invitation
Lead

Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy.
Iwata Shigeru, Nakayamada Shingo, Fukuyo Shunsuke, Kubo Satoshi, Yunoue Naoki, Wang Sheau-Pey, Yoshikawa Maiko, Saito Kazuyoshi, Tanaka Yoshiya
Arthritis & rheumatology (Hoboken, N.J.), Jan. 2015, Null, Null

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.
Maeshima Keisuke, Yamaoka Kunihiro, Kubo Satoshi, Nakano Kazuhisa, Iwata Shigeru, Saito Kazuyoshi, Ohishi Masanobu, Miyahara Hisaaki, Tanaka Shinya, Ishii Koji, Yoshimatsu Hironobu, Tanaka Yoshiya
Arthritis and rheumatism, Jun. 2012, Null, Null

Accelerated Type VII collagen turnover in systemic sclerosis patients, reflected by serological neo-epitope fragment biomarkers.
He Yi, Sand Jannie M B, Kubo Satoshi, Ohkubo Naoaki, Miyazaki Yusuke, Karsdal Morten, Tanaka Yoshiya, Bay-Jensen Anne-Christine
Arthritis research & therapy, Mar. 2025, Reviewed, No invitation

Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study.
Miyagawa Ippei, Nakayamada Shingo, Ueno Masanobu, Miyazaki Yusuke, Iwata Shigeru, Kubo Satoshi, Sonomoto Koshiro, Anan Junpei, Ohkubo Naoaki, Inoue Yoshino, Tanaka Yoshiya
Arthritis research & therapy, Apr. 2022, Reviewed, No invitation

Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes.
Ueno Masanobu, Miyagawa Ippei, Miyazaki Yusuke, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Nakayamada Shingo, Tanaka Yoshiya
Arthritis research & therapy, Oct. 2022, Reviewed, No invitation

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
Masanobu Ueno, Ippei Miyagawa, Takafumi Aritomi, Koichi Kimura, Shigeru Iwata, Kentaro Hanami, Syunsuke Fukuyo, Satoshi Kubo, Yusuke Miyazaki, Shingo Nakayamada, Yoshiya Tanaka
Arthritis research & therapy, Jun. 2022, Reviewed, No invitation

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis.
Ueno Masanobu, Miyagawa Ippei, Nakano Kazuhisa, Iwata Shigeru, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Miyazaki Yusuke, Kawabe Akio, Yoshinari Hiroko, Nakayamada Shingo, Tanaka Yoshiya
Arthritis research & therapy, Mar. 2021, Reviewed, No invitation

Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study.
Miyazaki Yusuke, Nakano Kazuhisa, Nakayamada Shingo, Kubo Satoshi, Iwata Shigeru, Hanami Kentaro, Fukuyo Shunsuke, Miyagawa Ippei, Yamaguchi Ayako, Kawabe Akio, Saito Kazuyoshi, Tanaka Yoshiya
Arthritis research & therapy, Jun. 2021, Reviewed, No invitation

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation.
Miyazaki Yusuke, Nakayamada Shingo, Kubo Satoshi, Ishikawa Yuichi, Yoshikawa Maiko, Sakata Kei, Iwata Shigeru, Miyagawa Ippei, Nakano Kazuhisa, Tanaka Yoshiya
Arthritis research & therapy, Jun. 2020, Reviewed, No invitation

Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry.
Kawabe Akio, Nakano Kazuhisa, Kubo Satoshi, Asakawa Takeshi, Tanaka Yoshiya
Arthritis research & therapy, Jun. 2020, Reviewed, No invitation

Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease.
Miyagawa Ippei, Nakano Kazuhisa, Iwata Shigeru, Nakayamada Shingo, Saito Kazuyoshi, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Kawabe Akio, Miyazaki Yusuke, Tanaka Yoshiya
Arthritis research & therapy, Jun. 2019, Reviewed, No invitation

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
Nakayamada Shingo, Kubo Satoshi, Iwata Shigeru, Tanaka Yoshiya
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, Oct. 2016, Null, Null

Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability.
Narisawa Manabu, Kubo Satoshi, Okada Yosuke, Yamagata Kaoru, Nakayamada Shingo, Sakata Kei, Yamaoka Kunihiro, Tanaka Yoshiya
Bone, Jan. 2021, Reviewed, No invitation

Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10.
Tanaka Kenichi, Yamagata Kaoru, Kubo Satoshi, Nakayamada Shingo, Sakata Kei, Matsui Takanori, Yamagishi Sho-Ichi, Okada Yosuke, Tanaka Yoshiya
Bone, Aug. 2019, Reviewed, No invitation

Abatacept therapy reduces CD28+CXCR5+ follicular helper like T cells in patients with rheumatoid arthritis.
Fukuyo S, Nakayamada S, Iwata S, Kubo S, Saito K, Tanaka Y.
Clin Exp Rheumatol, 2017, Reviewed, Null

B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus
Tanaka Y, Kubo S, Iwata S, Yoshikawa M, Nakayamada S.
Clinical Immunology, Jan. 2018, Not reviewed, Null

Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.
Kubo Satoshi, Nakano Kazuhisa, Nakayamada Shingo, Hirata Shintaro, Fukuyo Shunsuke, Sawamukai Norifumi, Saito Kazuyoshi, Tanaka Yoshiya
Clinical and experimental rheumatology, 2016, Null, Null
Lead

Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus.
Yoshikawa Maiko, Nakayamada Shingo, Kubo Satoshi, Nawata Aya, Kitanaga Yukihiro, Iwata Shigeru, Sakata Kei, Ma Xiaoxue, Wang Sheau Pey, Nakano Kazuhisa, Saito Kazuyoshi, Tanaka Yoshiya
Clinical immunology (Orlando, Fla.), Mar. 2019, Reviewed, No invitation

Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching.
Kubo Satoshi, Nakayamada Shingo, Nakano Kazuhisa, Sawamukai Norifumi, Hirata Shintaro, Hanami Kentaro, Saito Kazuyoshi, Tanaka Yoshiya
Clinical immunology (Orlando, Fla.), Apr. 2018, Reviewed, Null
Lead

B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus.
Tanaka Yoshiya, Kubo Satoshi, Iwata Shigeru, Yoshikawa Maiko, Nakayamada Shingo
Clinical immunology (Orlando, Fla.), Apr. 2018, Reviewed, Null

Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report.
Kurozumi Akira, Okada Yosuke, Arao Tadashi, Miyazaki Yusuke, Yoshikawa Maiko, Torimoto Keiichi, Kubo Satoshi, Nakayamada Shingo, Tanaka Yoshiya
Endocrinology, diabetes & metabolism case reports, 2016, Null, Null

A wide perspective of targeted therapies for precision medicine in autoimmune diseases.
Miyagawa I, Kubo S, Tanaka Y.
Expert Review of Precision Medicine and Drug Development, Aug. 2020, Reviewed, No invitation

JAK inhibitors for rheumatoid arthritis
Satoshi Kubo, Shingo Nakayamada, Yoshiya Tanaka
Expert opinion on investigational drugs, Apr. 2023, Reviewed, No invitation
Lead

Chemical JAK inhibitors for the treatment of rheumatoid arthritis.
Nakayamada Shingo, Kubo Satoshi, Iwata Shigeru, Tanaka Yoshiya
Expert opinion on pharmacotherapy, Oct. 2016, Null, Null

Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update.
Kubo Satoshi, Nakayamada Shingo, Tanaka Yoshiya
Expert review of clinical immunology, Jul. 2019, Reviewed, No invitation
Lead

Baricitinib for the treatment of rheumatoid arthritis.
Kubo Satoshi, Nakayamada Shingo, Tanaka Yoshiya
Expert review of clinical immunology, Sep. 2016, Null, Null
Lead

Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis.
Miyazaki Yusuke, Nakayamada Shingo, Kubo Satoshi, Nakano Kazuhisa, Iwata Shigeru, Miyagawa Ippei, Ma Xiaoxue, Trimova Gulzhan, Sakata Kei, Tanaka Yoshiya
Frontiers in immunology, Dec. 2018, Reviewed, No invitation

Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus.
Sakata Kei, Nakayamada Shingo, Miyazaki Yusuke, Kubo Satoshi, Ishii Akina, Nakano Kazuhisa, Tanaka Yoshiya
Frontiers in immunology, Aug. 2018, Reviewed, No invitation

Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System.
Kubo Satoshi, Nakayamada Shingo, Sakata Kei, Kitanaga Yukihiro, Ma Xiaoxue, Lee Seunghyun, Ishii Akina, Yamagata Kaoru, Nakano Kazuhisa, Tanaka Yoshiya
Frontiers in immunology, 2018, Reviewed, No invitation
Lead

Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes.
Miyagawa Ippei, Nakayamada Shingo, Ueno Masanobu, Miyazaki Yusuke, Ohkubo Naoaki, Inoue Yoshino, Kubo Satoshi, Tanaka Yoshiya
Frontiers in medicine, Jul. 2022, Reviewed, No invitation

Evolution of diagnostic criteria and new insights into clinical testing in mixed connective tissue disease; anti-survival motor neuron complex antibody as a novel marker of severity of the disease.
Kubo Satoshi, Tanaka Yoshiya
Immunological medicine, Jun. 2024, Reviewed, No invitation
Lead

The role of nailfold videocapillaroscopy in patients with systemic sclerosis.
Kubo Satoshi, Smith Vanessa, Cutolo Maurizio, Tanaka Yoshiya
Immunological medicine, Sep. 2018, Reviewed, No invitation
Lead

胸水中アデノシンデアミナーゼ上昇を伴うIgG4関連胸膜炎(IgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion)
Nagayasu Atsushi, Kubo Satoshi, Nakano Kazuhisa, Nakayamada Shingo, Iwata Shigeru, Miyagawa Ippei, Fukuyo Shunsuke, Saito Kazuyoshi, Tanaka Yoshiya
Internal Medicine, Aug. 2018, Reviewed, Null

Spontaneous Remission in a Patient with Anti-OJ Autoantibodies-positive Anti-synthetase Syndrome Following SARS-CoV-2 Infection and mRNA Vaccination: A Case Report.
Todoroki Yasuyuki, Nakayamada Shingo, Miyagawa Ippei, Kubo Satoshi, Yoshioka Kiyotake, Satoh Minoru, Tanaka Yoshiya
Internal medicine (Tokyo, Japan), Mar. 2025, Reviewed, No invitation

An Autopsy Case with Cerebral Hemorrhaging due to disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis.
Ueno Masanobu, Nakano Kazuhisa, Yoshinari Hiroko, Nakayamada Shingo, Iwata Shigeru, Kubo Satoshi, Miyagawa Ippei, Tanaka Yoshiya
Internal medicine (Tokyo, Japan), Apr. 2019, Reviewed, No invitation

Pleurisy Caused by Mycobacterium abscessus in a Young Patient with Dermatomyositis: A Case Report and Brief Review of the Literature.
Noguchi Shingo, Hanami Kentaro, Miyata Hiroko, Torii Ryo, Shimabukuro Ikuko, Kubo Satoshi, Obata Hideto, Yoshii Chiharu, Yatera Kazuhiro
Internal medicine (Tokyo, Japan), Apr. 2018, Reviewed, No invitation

Discovery of a novel Igβ and FcγRIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus.
Kitanaga Yukihiro, Yamajuku Daisuke, Kubo Satoshi, Nakamura Koji, Maeda Masashi, Seki Mutsumi, Kaneko Yoko, Kinugasa Fumitaka, Morokata Tatsuaki, Kondo Yuya, Yoshinari Hiroko, Nakayamada Shingo, Sumida Takayuki, Tanaka Yoshiya
International immunopharmacology, Dec. 2021, Reviewed, No invitation

Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis.
Kubo Satoshi, Siebuhr Anne Sofie, Bay-Jensen Anne-C, Juhl Pernille, Karsdal Morten A, Satoh Yurie, Todoroki Yasuyuki, Nakano Kazuhisa, Nakayamada Shingo, Tanaka Yoshiya
International journal of rheumatic diseases, Feb. 2020, Reviewed, No invitation
Lead

The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
Miyagawa Ippei, Nakano Kazuhisa, Nakayamada Shingo, Iwata Shigeru, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Kawabe Akio, Miyazaki Yusuke, Inoue Yoshino, Ueno Masanobu, Ohkubo Naoaki, Fujita Yuya, Tanaka Yoshiya
International journal of rheumatic diseases, Feb. 2020, Reviewed, No invitation

Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus.
Miyagawa Ippei, Nakano Kazuhisa, Nakayamada Shingo, Iwata Shigeru, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Inoue Yoshino, Ueno Masanobu, Tanaka Yoshiya
International journal of rheumatic diseases, Mar. 2019, Reviewed, No invitation

Possible involvement of CXCR3-CXCR6 + CD4 + T cells in Langerhans cell histiocytosis.
Tokutsu Akemi, Okada Yosuke, Kurozumi Akira, Tanaka Kenichi, Kubo Satoshi, Tanaka Yoshiya
Journal of bone and mineral metabolism, Jan. 2023, Reviewed, No invitation

Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study.
Tanaka Yoshiya, Mori Hiroko, Aoki Takatoshi, Atsumi Tatsuya, Kawahito Yutaka, Nakayama Hisanori, Tohma Shigeto, Yamanishi Yuji, Hasegawa Hitoshi, Tanimura Kazuhide, Negoro Nobuo, Ueki Yukitaka, Kawakami Atsushi, Eguchi Katsumi, Saito Kazuyoshi, Okada Yosuke
Journal of bone and mineral metabolism, Nov. 2016, Reviewed, No invitation

Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.
Iwata S,Saito K,Hirata S,Ohkubo N,Nakayamada S,Nakano K,Hanami K,Kubo S, Miyagawa I,Yoshikawa M,Miyazaki Y,Yoshinari H,Tanaka Y.
Lupus, Apr. 2018, Reviewed, No invitation

A case of Buerger's disease with vasculopathy and skin fibrosis requiring differential diagnosis from systemic sclerosis
Masashi Funada, Shingo Nakayamada, Shunsuke Fukuyo, Satoshi Kubo, Aya Nawata, Yuya Fujita, Yoshiya Tanaka
Modern Rehumatology Case Reports, Jan. 2025, Reviewed, No invitation

The two cases of acute acalculous cholecystitis associated with systemic lupus erythematosus (SLE) presented different clinical aspects
Satoh Y, Nakano K, Miyazaki Y, Nakayamada S, Fukuyo S, Kubo S, Miyagawa I, Yoshinari H, Saito K, Satoh M, Tanaka Y
Modern Rheumatology Case Reports, Jan. 2019, Reviewed, No invitation

コルチコステロイド/メトトレキサート抵抗性紅斑性天疱瘡を伴う血清反応陰性関節リウマチに対してエタネルセプト投与が奏効した1例(Successful treatment with etanercept in a case of seronegative rheumatoid arthritis with corticosteroid/methotrexate-resistant pemphigus erythematosus)
Ohkubo Naoaki, Nakano Kazuhisa, Miyagawa Ippei, Iwata Shigeru, Fukuyo Shunsuke, Kubo Satoshi, Tamaki Yasutaro, Nakayamada Shingo, Tanaka Yoshiya
Modern Rheumatology Case Reports, Jul. 2018, Reviewed, Null

The abundance of regulatory T cell subsets is associated with the clinical outcomes of sarcoidosis.
Kusaka Katsuhide, Miyazaki Yusuke, Nakayamada Shingo, Kubo Satoshi, Miyagawa Ippei, Satoh-Kanda Yurie, Todoroki Yasuyuki, Ueno Masanobu, Tanaka Yoshiya
Modern rheumatology, Apr. 2025, Reviewed, No invitation

The 2023 revised diagnostic criteria for IgG4-related dacryoadenitis and sialadenitis.
Kanda Masatoshi, Nagahata Ken, Moriyama Masafumi, Takano Ken-Ichi, Kamekura Ryuta, Yoshifuji Hajime, Tsuboi Hiroto, Yamamoto Motohisa, Umehara Hisanori, Umeda Masataka, Sakamoto Mizuki, Maehara Takashi, Inoue Yoshino, Kubo Satoshi, Himi Tetsuo, Origuchi Tomoki, Masaki Yasufumi, Mimori Tsuneyo, Dobashi Hiroaki, Tanaka Yoshiya, Nakamura Seiji, Takahashi Hiroki
Modern rheumatology, Apr. 2025, Reviewed, No invitation

5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study.
Yamaguchi Ayako, Hirata Shintaro, Kubo Satoshi, Fukuyo Shunsuke, Hanami Kentaro, Nakano Kazuhisa, Nakayamada Shingo, Saito Kazuyoshi, Tanaka Yoshiya
Modern rheumatology, Jan. 2020, Reviewed, No invitation

Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.
Nakano Kazuhisa, Saito Kazuyoshi, Nawata Aya, Hanami Kentaro, Kubo Satoshi, Miyagawa Ippei, Fujino Yoshihisa, Nakayamada Shingo, Tanaka Yoshiya
Modern rheumatology, Mar. 2020, Reviewed, No invitation

Immunophenotype involved in IgG4-related disease.
Kubo Satoshi, Nakayamada Shingo, Tanaka Yoshiya
Modern rheumatology, Mar. 2019, Reviewed, No invitation
Lead

Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.
Hirata Shintaro, Li Wanying, Kubo Satoshi, Fukuyo Shunsuke, Mizuno Yasushi, Hanami Kentaro, Sawamukai Norifumi, Yamaoka Kunihiro, Saito Kazuyoshi, Defranoux Nadine A, Tanaka Yoshiya
Modern rheumatology, Nov. 2016, Null, Null

Association of plasmacytoid dendritic cells with B cell infiltration in minor salivary glands in patients with Sjögren's syndrome.
Zhao Jidong, Kubo Satoshi, Nakayamada Shingo, Shimajiri Shohei, Zhang Xiangmei, Yamaoka Kunihiro, Tanaka Yoshiya
Modern rheumatology, Sep. 2016, Null, Null

Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study.
Kubo Satoshi, Saito Kazuyoshi, Hirata Shintaro, Fukuyo Shunsuke, Yamaoka Kunihiro, Sawamukai Norifumi, Nawata Masao, Iwata Shigeru, Mizuno Yasushi, Tanaka Yoshiya
Modern rheumatology, Jan. 2014, Reviewed, Null
Lead

A case of Buerger's disease with vasculopathy and skin fibrosis requiring differential diagnosis from systemic sclerosis.
Funada Masashi, Nakayamada Shingo, Fukuyo Shunsuke, Kubo Satoshi, Nawata Aya, Fujita Yuya, Tanaka Yoshiya
Modern rheumatology case reports, Jul. 2024, Reviewed, No invitation

A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related disease.
Kanda Ryuichiro, Kubo Satoshi, Nakano Kazuhisa, Kawabe Akio, Nawata Aya, Hanami Kentaro, Nakayamada Shingo, Tanaka Yoshiya
Modern rheumatology case reports, Jul. 2020, Reviewed, No invitation

Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators.
Kusaka Katsuhide, Nakano Kazuhisa, Iwata Shigeru, Kubo Satoshi, Nishida Tomoya, Tanaka Yoshiya
Modern rheumatology case reports, Jul. 2020, Reviewed, No invitation

The immune health metric as an indicator of health and disease.
Kubo Satoshi, Tanaka Yoshiya
Nature reviews. Rheumatology, Sep. 2024, Reviewed, No invitation
Lead

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study.
Kubo Satoshi, Miyazaki Yusuke, Amano Koichi, Matsui Kiyoshi, Kameda Hideto, Inoue Yoshino, Nakayamada Shingo, Ogura Takehisa, Kaneko Yuko, Yamaoka Kunihiro, Tanaka Yoshiya
RMD open, Apr. 2023, Reviewed, No invitation
Lead

Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease.
Kubo Satoshi, Kanda Ryuichiro, Nawata Aya, Miyazaki Yusuke, Kawabe Akio, Hanami Kentaro, Nakatsuka Keisuke, Saito Kazuyoshi, Nakayamada Shingo, Tanaka Yoshiya
RMD open, Mar. 2022, Reviewed, No invitation
Lead

Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry.
Miyazaki Yusuke, Nakayamada Shingo, Tanaka Hiroaki, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Yamaguchi Ayako, Miyagawa Ippei, Satoh-Kanda Yurie, Todoroki Yasuyuki, Inoue Yoshino, Ueno Masanobu, Tanaka Yoshiya
RMD open, Jan. 2025, Reviewed, No invitation

Association of peripheral CD8+ T cell activation with disease activity and treatment resistance in systemic lupus erythematosus.
Fujita Yuya, Nakayamada Shingo, Kubo Satoshi, Miyazaki Yusuke, Sonomoto Koshiro, Tanaka Hiroaki, Tanaka Yoshiya
RMD open, Feb. 2025, Reviewed, No invitation

Induction of interleukin 21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus.
Ueno Masanobu, Iwata Shigeru, Yamagata Kaoru, Todoroki Yasuyuki, Sonomoto Koshiro, Nagayasu Atsushi, Miyagawa Ippei, Kubo Satoshi, Miyazaki Yusuke, Miyata Hiroko, Kanda Ryuichiro, Aritomi Takafumi, Nakayamada Shingo, Tanaka Yoshiya
RMD open, Dec. 2024, Reviewed, No invitation

Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus.
Satoh-Kanda Yurie, Nakayamada Shingo, Kubo Satoshi, Yamagata Kaoru, Nawata Aya, Tanaka Hiroaki, Kosaka Shunpei, Kanda Ryuichiro, Yu Shan, Fujita Yuya, Sonomoto Koshiro, Tanaka Yoshiya
RMD open, Jun. 2024, Reviewed, No invitation

Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis.
Nakayamada S, Kubo S, Yoshikawa M, Miyazaki Y, Yunoue N, Iwata S, Miyagawa I, Hirata S, Nakano S, Saito K, Tanaka Y.
Rheumatology, Apr. 2018, Reviewed, No invitation

Efficacy, safety, and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry.
Sakai Hidenori, Miyazaki Yusuke, Nakayamada Shingo, Kubo Satoshi, Hanami Kentaro, Fukuyo Shunsuke, Yamaguchi Ayako, Miyagawa Ippei, Ueno Masanobu, Tanaka Hiroaki, Todoroki Yasuyuki, Ohkubo Naoaki, Funada Masashi, Matsunaga Satsuki, Tanaka Yoshiya
Rheumatology (Oxford, England), Sep. 2024, Reviewed, No invitation

Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST study.
Miyazaki Yusuke, Nakayamada Shingo, Tanaka Hiroaki, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Miyagawa Ippei, Yamaguchi Ayako, Todoroki Yasuyuki, Inoue Yoshino, Ueno Masanobu, Tanaka Yoshiya
Rheumatology (Oxford, England), Jun. 2024, Reviewed, No invitation

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study.
Sonomoto Koshiro, Nakayamada Shingo, Fujino Yoshihisa, Miyata Hiroko, Kubo Satoshi, Fujita Yuya, Inoue Yoshino, Matsunaga Satsuki, Iwata Shigeru, Hanami Kentaro, Todoroki Yasuyuki, Yoshinari-Korekoda Hiroko, Kawabe Akio, Yamaguchi Ayako, Ueno Masanobu, Satoh-Kanda Yurie, Kanda Ryuichiro, Funada Masashi, Ohkubo Naoaki, Kusaka Katsuhide, Kosaka Shumpei, Nagayasu Atsushi, Fukuyo Shunsuke, Nawata Masao, Miyazaki Yusuke, Tokunaga Mikiko, Tanaka Kenichi, Okada Yosuke, Tanaka Yoshiya
Rheumatology (Oxford, England), Nov. 2023, Reviewed, No invitation

Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry.
Miyazaki Yusuke, Funada Masashi, Nakayamada Shingo, Sonomoto Koshiro, Tanaka Hiroaki, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Yamaguchi Ayako, Miyagawa Ippei, Todoroki Yasuyuki, Ueno Masanobu, Tanaka Yoshiya
Rheumatology (Oxford, England), Sep. 2024, Reviewed, No invitation

Predictors of the effectiveness to first-line CTLA4-Ig in patients with rheumatoid arthritis: the FIRST registry.
Kobayashi Hiroki, Miyazaki Yusuke, Nakayamada Shingo, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Yamaguchi Ayako, Inoue Yoshino, Todoroki Yasuyuki, Miyata Hiroko, Tanaka Hiroaki, Fujino Yoshihisa, Hirata Shintaro, Tanaka Yoshiya
Rheumatology (Oxford, England), May 2025, Reviewed, No invitation

Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from FIRST registry.
Kubo Satoshi, Miyazaki Yusuke, Tanaka Hiroaki, Fujita Yuya, Sakai Hidenori, Ueno Masanobu, Todoroki Yasuyuki, Satoh-Kanda Yurie, Miyagawa Ippei, Nakayamada Shingo, Tanaka Yoshiya
Rheumatology (Oxford, England), May 2025, Reviewed, No invitation
Lead

In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors.
Kitanaga Yukihiro, Imamura Emiko, Nakahara Yutaka, Fukahori Hidehiko, Fujii Yasutomo, Kubo Satoshi, Nakayamada Shingo, Tanaka Yoshiya
Rheumatology (Oxford, England), Nov. 2019, Reviewed, No invitation

Interleukin-23 drives expansion of Thelper 17 cells through epigenetic regulation by signal transducer and activators of transcription 3 in lupus patients.
Lee Seunghyun, Nakayamada Shingo, Kubo Satoshi, Yamagata Kaoru, Yoshinari Hiroko, Tanaka Yoshiya
Rheumatology (Oxford, England), May 2020, Reviewed, No invitation

Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in mixed connective tissue disease.
Todoroki Yasuyuki, Satoh Minoru, Kubo Satoshi, Kosaka Shunpei, Fukuyo Shunsuke, Nakatsuka Keisuke, Saito Kazuyoshi, Tanaka Shin, Nakayamada Shingo, Tanaka Yoshiya
Rheumatology (Oxford, England), Apr. 2024, Reviewed, No invitation

T helper cells expressing fractalkine receptor and bearing T follicular helper 1-like cell functions in patients with IgG4-related disease.
Inoue Yoshino, Nakayamada Shingo, Kubo Satoshi, Yamagata Kaoru, Sonomoto Koshiro, Iwata Shigeru, Miyazaki Yusuke, Tanaka Yoshiya
Rheumatology (Oxford, England), Aug. 2022, Reviewed, No invitation

Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD.
Todoroki Yasuyuki, Kubo Satoshi, Nakano Kazuhisa, Miyazaki Yusuke, Ueno Masanobu, Satoh-Kanda Yurie, Kanda Ryuichiro, Miyagawa Ippei, Hanami Kentaro, Nakatsuka Keisuke, Saito Kazuyoshi, Nakayamada Shingo, Tanaka Yoshiya
Rheumatology (Oxford, England), Mar. 2022, Reviewed, No invitation

Scleroderma in an ice-cream shop worker.
Kubo Satoshi, Tanaka Yoshiya
Rheumatology (Oxford, England), Dec. 2018, Reviewed, No invitation
Lead

Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis.
Kubo Satoshi, Nakayamada Shingo, Miyazaki Yusuke, Yoshikawa Maiko, Yoshinari Hiroko, Satoh Yurie, Todoroki Yasuyuki, Nakano Kazuhisa, Satoh Minoru, Smith Vanessa, Cutolo Maurizio, Tanaka Yoshiya
Rheumatology (Oxford, England), Jun. 2019, Reviewed, No invitation
Lead

Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies.
Kubo Satoshi, Todoroki Yasuyuki, Nakayamada Shingo, Nakano Kazuhisa, Satoh Minoru, Nawata Aya, Satoh Yurie, Miyagawa Ippei, Saito Kazuyoshi, Smith Vanessa, Cutolo Maurizio, Tanaka Yoshiya
Rheumatology (Oxford, England), Jan. 2019, Reviewed, Null
Lead

Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis.
Nakayamada Shingo, Kubo Satoshi, Yoshikawa Maiko, Miyazaki Yusuke, Yunoue Naoki, Iwata Shigeru, Miyagawa Ippei, Hirata Shintaro, Nakano Kazuhisa, Saito Kazuyoshi, Tanaka Yoshiya
Rheumatology (Oxford, England), Mar. 2017, Null, Null

Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation.
Wang Sheau-Pey, Iwata Shigeru, Nakayamada Shingo, Niiro Hiroaki, Jabbarzadeh-Tabrizi Siamak, Kondo Masahiro, Kubo Satoshi, Yoshikawa Maiko, Tanaka Yoshiya
Rheumatology (Oxford, England), Aug. 2015, Null, Null

Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry.
Kanda Ryuichiro, Miyazaki Yusuke, Nakayamada Shingo, Fukuyo Shunsuke, Kubo Satoshi, Miyagawa Ippei, Yamaguchi Ayako, Satoh-Kanda Yurie, Ohkubo Naoaki, Todoroki Yasuyuki, Tanaka Hiroaki, Ueno Masanobu, Nagayasu Atsushi, Fujita Yuya, Aritomi Takafumi, Kusaka Katsuhide, Sakai Hidenori, Matsunaga Satsuki, Nohara Hirotsugu, Tanaka Yoshiya
Rheumatology and therapy, Mar. 2025, Reviewed, No invitation

Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis.
Nagayasu Atsushi, Miyazaki Yusuke, Sonomoto Koshiro, Kubo Satoshi, Miyagawa Ippei, Yamaguchi Ayako, Tanaka Hiroaki, Todoroki Yasuyuki, Ueno Masanobu, Aritomi Takafumi, Fujita Yuya, Sakai Hidenori, Suzuki Katsunori, Nakayamada Shingo, Tanaka Yoshiya
Rheumatology and therapy, Aug. 2025, Reviewed, No invitation

Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry.
Kubo Satoshi, Miyazaki Yusuke, Todoroki Yasuyuki, Nagayasu Atsushi, Kanda Ryuichiro, Aritomi Takafumi, Matsunaga Satsuki, Ueno Masanobu, Miyagawa Ippei, Sonomoto Koshiro, Hanami Kentaro, Nakayamada Shingo, Tanaka Yoshiya
Rheumatology and therapy, Oct. 2023, Reviewed, No invitation
Lead

Regulation of fibronectin and collagens type I, III and VI by TNF-α, TGF-β, IL-13, and tofacitinib.
Gillesberg Frederik S, Pehrsson Martin, Bay-Jensen Anne-Christine, Frederiksen Peder, Karsdal Morten, Deleuran Bent W, Kragstrup Tue W, Kubo Satoshi, Tanaka Yoshiya, Mortensen Joachim H
Scientific reports, Jan. 2025, Reviewed, No invitation

Comprehensive immunophenotypic analysis reveals the pathological involvement of Th17 cells in Graves' disease.
Torimoto Keiichi, Okada Yosuke, Nakayamada Shingo, Kubo Satoshi, Kurozumi Akira, Narisawa Manabu, Tanaka Yoshiya
Scientific reports, Oct. 2022, Reviewed, No invitation

Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases✰.
Tanaka Yoshiya, Kubo Satoshi, Miyagawa Ippei, Iwata Shigeru, Nakayamada Shingo
Seminars in arthritis and rheumatism, Jun. 2019, Reviewed, No invitation

Th22 cells promote osteoclast differentiation via production of IL-22.
Miyazaki Y,Nakayamada S,Kubo S,Nakano K,Iwata S,Miyagawa I,Ma X,Trimova G, Sakata K,Tanaka Y.
免疫Immunology Frontier, Apr. 2018, Reviewed, No invitation

Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus
Sakata K,Nakayamada S,Miyazaki Y,Kubo S,Nakano K,Tanaka Y.
免疫Immunology Frontier, Aug. 2018, Reviewed, No invitation

SLE/NPSLE ヒトB細胞の完全活性化に関するBtkとインターロイキン(IL)-21の役割(SLE/NPSLE 1 The role of Btk and IL-21 for the full activation of human B cells)
Wang Sheau-Pey, Iwata Shigeru, Yamaoka Kunihiro, Niiro Hiroaki, Nakayamada Shingo, Siamak Jabbarzadeh Tabrizi, Kubo Satoshi, Kondo Masahiro, Akashi Koichi, Tanaka Yoshiya
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.
Iwata Shigeru, Saito Kazuyoshi, Tokunaga Mikiko, Yamaoka Kunihiro, Nawata Masao, Yukawa Sonosuke, Hanami Kentaro, Fukuyo Shunsuke, Miyagawa Ippei, Kubo Satoshi, Tanaka Yoshiya
The Journal of rheumatology, Apr. 2011, Null, Null

アバタセプト
久保智史, 田中良哉, Contributor
日本臨床社, Apr. 2022, Reviewed

Nailfold video capillaroscopy （ 爪郭部毛細血管ビデオ顕微鏡 ）
久保智史、田中良哉, Contributor
南江堂, Feb. 2025, Reviewed